During the two-year TARGET-PCI (Thrombocyte Activity Reassessment and GenoTyping for PCI) trial, Paul A. Gurbel, MD, of the Sinai Center for Thrombosis Research in Baltimore, and colleagues will use the Verigene System point-of-care assay (Verigene IUO CBS Assay CYP219) to identify genotypes associated with the responsiveness of clopidogrel (Plavix, Bristol-Myers Squibb/Sanofi-Aventis).
